Shield Therapeutics plc (LON:STX – Get Free Report)’s share price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 6.27 and traded as low as GBX 6. Shield Therapeutics shares last traded at GBX 6.50, with a volume of 575,290 shares changing hands.
Shield Therapeutics Stock Performance
The company has a debt-to-equity ratio of -199.87, a current ratio of 0.90 and a quick ratio of 2.16. The stock has a 50-day moving average price of GBX 6.27 and a 200-day moving average price of GBX 8.33. The firm has a market capitalization of £69.52 million, a PE ratio of -3.25 and a beta of 1.76.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet
- Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises
- 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks
- Why Wall Street Suddenly Sees SpaceX as an AI Company
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
